Bulletin
Investor Alert

New York Markets Open in:

press release

June 9, 2022, 4:03 p.m. EDT

Revolution Medicines to Participate in the 43rd Annual Goldman Sachs Global Healthcare Conference

REDWOOD CITY, Jun 09, 2022 (GLOBE NEWSWIRE via COMTEX) -- REDWOOD CITY, Calif., June 09, 2022 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. /zigman2/quotes/216320743/composite RVMD -2.32% , a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today announced that the company will participate in the 43 [rd] Annual Goldman Sachs Global Healthcare Conference. Mark A. Goldsmith, M.D., Ph.D., chief executive officer and chairman of Revolution Medicines, will be the featured participant in a live fireside chat at the event.

Details of the company's participation are as follows:

  • Conference Date: June 13 - 16, 2022

  • Fireside Chat Details: 1:20 p.m. Pacific on Wednesday, June 15, 2022

A live webcast of the fireside chat can be accessed at: https://ir.revmed.com/events-and-presentations . An archived replay of the webcast will be available on the investors section of the company's website for at least 14 days following the event.

About Revolution Medicines, Inc.

Revolution Medicines is a clinical-stage oncology company developing novel targeted therapies for RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) Inhibitors designed to suppress diverse oncogenic variants of RAS proteins, and RAS Companion Inhibitors for use in combination treatment strategies. RAS(ON) Inhibitors in development include RMC-6236 (RAS [MULTI] ), RMC-6291(KRAS [G12C] ), RMC-9805 (KRAS [G12D] ) and RMC-8839 (KRAS [G13C] ), and a pipeline of research compounds targeting additional RAS variants. RAS Companion Inhibitors in clinical development include RMC-4630 (SHP2) and RMC-5552 (mTORC1/4EBP1).







        Contact Information
        
        David S. Arrington
        SVP Investor Relations & Corporate Affairs
        Revolution Medicines
        650-542-6046
        darrington@revmed.com
        


COMTEX_408446871/2471/2022-06-09T16:02:57

Is there a problem with this press release? Contact the source provider Comtex at editorial@comtex.com. You can also contact MarketWatch Customer Service via our Customer Center.

(C) Copyright 2022 GlobeNewswire, Inc. All rights reserved.

/zigman2/quotes/216320743/composite
US : U.S.: Nasdaq
$ 24.40
-0.58 -2.32%
Volume: 1.27M
Aug. 8, 2022 4:00p
P/E Ratio
N/A
Dividend Yield
N/A
Market Cap
$2.14 billion
Rev. per Employee
$142,750
loading...

Partner Center

Link to MarketWatch's Slice.